Abstract: The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI (“Factor XIa”).

Abstract: The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient.

Abstract: The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI (“Factor XIa”).

Abstract: The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient.

Abstract: The present invention relates to methods and pharmaceutical compositions for renal protection in a mammal in need thereof, such as a mammal having a disease manifested by atrial enlargement and/or remodeling or suffering from hypertension or heart failure or being prone to suffering from hypertension and/or heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said mammal.

Abstract: The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.

Abstract: The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.

Abstract: The invention relates to a thin film coated array and the process of fabricating and using the array including methods of etching, depositing a thin film coating, preparing and using the thin film coated array.

Abstract: This invention relates to microwell array compositions which are coated with one or more thin film coatings. The invention includes the process of fabricating and using thin film coated microwell arrays.

Abstract: The roaming of a wireless device 115 extends the effective range of a wireless network 100 by passing a device 115 between access points as the device leaves the coverage area of one and enters another. Roaming can be slow and problematic if an old link is disconnected prior to establishing a new link, especially if authentication and security is required. The present invention speeds up roaming by using existing mechanisms to initiate a new link with a new access point 120 prior to disconnecting the old link with an old access point 110.

Abstract: The roaming of a wireless device 115 extends the effective range of a wireless network 100 by passing a device 115 between access points as the device leaves the coverage area of one and enters another. Roaming can be slow and problematic if an old link is disconnected prior to establishing a new link, especially if authentication and security is required. The present invention speeds up roaming by using existing mechanisms to initiate a new link with a new access point 120 prior to disconnecting the old link with an old access point 110.